Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Macrogenics (NQ: MGNX )

3.590 +0.060 (+1.70%)
Streaming Delayed Price Updated: 12:39 PM EDT, Oct 3, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Macrogenics

< Previous 1 2 3 4 Next >
MACROGENICS, INC. (NASDAQ: MGNX) INVESTOR ALERT: Investors With Large Losses in MacroGenics, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights
From Bernstein Liebhard LLP
Via GlobeNewswire
Rosen Law Firm Urges MacroGenics, Inc. (NASDAQ: MGNX) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
From The Rosen Law Firm, P.A.
Via Business Wire
MacroGenics to Participate in Upcoming Investor Conference
From MacroGenics, Inc.
Via GlobeNewswire
MacroGenics Inc. (NASDAQ: MGNX) Leading the Way in Thursday Trading Based on Percentage Gain
Via Investor Brand Network
MacroGenics Inc. (NASDAQ: MGNX) is a Stock Spotlight on 3/5
Via Investor Brand Network
MacroGenics Inc. (NASDAQ: MGNX) is a Stock Spotlight on 2/12
Via Investor Brand Network
MACROGENICS ALERT: Bragar Eagel & Squire, P.C. is Investigating MacroGenics, Inc. on Behalf of MacroGenics Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Kirby McInerney LLP Announces Investigation of Shareholder Claims Against MacroGenics, Inc. (MGNX)
From Kirby McInerney LLP
Via Business Wire
MacroGenics to Participate in Upcoming Investor Conferences
From MacroGenics, Inc.
Via GlobeNewswire
MacroGenics Inc. (NASDAQ: MGNX) is a Stock Spotlight on 2/6
Via Investor Brand Network
MacroGenics Inc. (NASDAQ: MGNX) is a Stock Spotlight on 2/1
Via Investor Brand Network
MacroGenics Inc. (NASDAQ: MGNX) is a Stock Spotlight on 1/23
Via Investor Brand Network
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against MacroGenics, Inc. and Encourages Investors to Contact the Firm
From Schall Law
Via GlobeNewswire
MacroGenics Announces Date of First Quarter 2024 Financial Results Conference Call
From MacroGenics, Inc.
Via GlobeNewswire
MacroGenics Provides Phase 2 TAMARACK Study Early Interim Safety Data and Plans for Future Disclosures
From MacroGenics, Inc.
Via GlobeNewswire
MacroGenics to Participate in Upcoming Investor Conferences
From MacroGenics, Inc.
Via GlobeNewswire
MacroGenics Announces Date of Fourth Quarter 2023 Financial Results Conference Call
From MacroGenics, Inc.
Via GlobeNewswire
MacroGenics to Participate in Upcoming Investor Conference
From MacroGenics, Inc.
Via GlobeNewswire
MacroGenics to Participate in Upcoming Investor Conference
From MacroGenics, Inc.
Via GlobeNewswire
MacroGenics to Participate in Upcoming Investor Conferences
From MacroGenics, Inc.
Via GlobeNewswire
MacroGenics Announces Date of Third Quarter 2023 Financial Results Conference Call
From MacroGenics, Inc.
Via GlobeNewswire
Elli Lilly Joins Big Pharma’s Multi-Billion-Dollar Oncology Race
Large pharmaceutical companies are increasingly investing in cancer treatment stocks, driven by the promise of medical breakthroughs and financial rewards. Eli Lilly became the latest Big Pharma giant... 
Via PressReach
MacroGenics Announces Achievement of $15 Million Milestone Related to Gilead’s Nomination of a Bispecific Research Program
From MacroGenics, Inc.
Via GlobeNewswire
MacroGenics to Participate in Upcoming Investor Conferences
From MacroGenics, Inc.
Via GlobeNewswire
MacroGenics Announces Date of Second Quarter 2023 Financial Results Conference Call
From MacroGenics, Inc.
Via GlobeNewswire
MacroGenics Announces Date of First Quarter 2023 Financial Results Conference Call
From MacroGenics, Inc.
Via GlobeNewswire
MacroGenics to Participate in Upcoming Investor Conferences
From MacroGenics, Inc.
Via GlobeNewswire
MacroGenics Earns $15 Million Milestone Following U.S. FDA Approval of ZYNYZ™ (retifanlimab-dlwr)
From MacroGenics, Inc.
Via GlobeNewswire
MacroGenics Announces Sale of TZIELD™ Royalty Interest for up to $200 Million
From MacroGenics, Inc.
Via GlobeNewswire
MacroGenics Announces Date of Fourth Quarter 2022 Financial Results Conference Call
From MacroGenics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.